Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MITF | O75030 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875253 | 0.89 | KMT2A (0.71) | KMT2AP2RX4THRBLMNACFTR | |
| SCHEMBL9977540 | 0.87 | P2RX3 (0.56) | KMT2AP2RX3CFTRMEN1KDM4E | |
| SCHEMBL4593864 | 0.87 | KMT2A (0.62) | KMT2AP2RX4THRBLMNACFTR | |
| SCHEMBL4594153 | 0.84 | KMT2A (0.56) | KMT2AP2RX4THRBLMNACFTR | |
| SCHEMBL9977523 | 0.81 | P2RX3 (0.50) | P2RX3CFTRKDM4ESMN1; SMN2PPARG | |
| Hydrochloric Acid SCHEMBL4594293 | 0.80 | P2RX3 (0.49) | P2RX3CFTRKDM4ESMN1; SMN2PPARG | |
| SCHEMBL10234498 | 0.75 | P2RX3 (0.45) | KMT2AP2RX3CFTRMEN1PPARG | |
| SCHEMBL28385438 | 0.74 | CFTR (0.58) | KMT2AP2RX4CFTRMAPTTBXA2R | |
| SCHEMBL439543 | 0.74 | CA1 (0.60) | TGM2LMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL6220005 | 0.74 | KMT2A (0.48) | KMT2AP2RX4TGM2THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207182-B2 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-1874733-B1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | GRUENENTHAL GMBH (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | GRUENENTHAL GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1874733-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111346-A1 | SUBSTITUTED CYCLIC UREA DERIVATIVES AND THE USE THEREOF AS VANILLOID RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090855-A1 | capsaicin receptor; to treat neuropathic pain; N-[4-[3-(4-tert-butylbenzyl)-2-thioxo-imidazolidinylmethyl]phenyl]methanesulfonamide | TRPV1, TRPA1, P2RX3 | KMT2A 4782/4885P2RX4 4/4885TGM2 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.